INGALLS & SNYDER LLC EPRX — EUPRAXIA PHARMACEUTICALS INC

Ownership history in INGALLS & SNYDER LLC  ·  6 quarters on record

AI Ownership Summary

INGALLS & SNYDER LLC reported EUPRAXIA PHARMACEUTICALS INC (EPRX) in 6 quarterly 13F filings from 2025 Q2 through 2026 Q3. Peak portfolio weight reached 0.02% in 2025 Q4. The latest visible filing shows EPRX at 0.02% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this EPRX ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was INGALLS & SNYDER LLC's position in EUPRAXIA PHARMACEUTICALS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q3

EPRX was reported at 0.02% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.02% in 2025 Q4

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2025 Q2 to 2026 Q3

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

EPRX stock page INGALLS & SNYDER LLC fund profile INGALLS & SNYDER LLC full holdings
How INGALLS & SNYDER LLC held EPRX — position size vs. price
% of Fund (quarterly)    EPRX price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 6 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q3 ADDED — — — 75,450 +7,000 +10.2% 0.02% $687 2026-11-12 $7.81
2026 Q2 REDUCED 9.5% +24.2% ❌ 68,450 -7,200 -9.5% 0.01% $452 2026-08-14 $6.72
2026 Q1 REDUCED — — — 75,650 -1,750 -2.3% 0.02% $548 2026-05-13 $7.55
2025 Q4 ADDED — — — 77,400 +18,300 +31.0% 0.02% $584K 2026-02-13 $8.42
2025 Q3 ADDED — — — 59,100 +21,900 +58.9% 0.01% $349K 2025-11-07 $5.45
2025 Q2 INITIATED — — — 37,200 — — 0.01% $214K 2025-07-31 $5.40

🏢 Other funds also holding EPRX

As of 2026 Q3 — sorted by position size

Vivo Capital, LLC 3Y 7Y 1.35% Aisling Capital Management LP 3Y 7Y 0.99% Affinity Asset Advisors, LLC 3Y 0.64% Beutel, Goodman & Co Ltd. 3Y 7Y 0.25% Stonepine Capital Management, LLC 3Y 7Y 0.23% Delaney Capital Management Ltd. 0.16% Annis Gardner Whiting Capital Advisors, LLC 3Y 0.08% SCOTIA CAPITAL INC. 3Y 7Y 0.04% AXQ CAPITAL, LP 3Y 0.02% PICTON MAHONEY ASSET MANAGEMENT 3Y 7Y 0.02%

FAQ About INGALLS & SNYDER LLC and EPRX

These are the practical questions this page is built to answer before you even open the full history table.

How long has INGALLS & SNYDER LLC reported owning EPRX?

INGALLS & SNYDER LLC reported EPRX across 6 quarterly 13F filings, from 2025 Q2 through 2026 Q3.

What was the largest reported EPRX position in INGALLS & SNYDER LLC's portfolio?

The largest reported portfolio weight for EPRX was 0.02% in 2025 Q4.

What is the latest reported EPRX position on this page?

The most recent filing on this page is 2026 Q3, when INGALLS & SNYDER LLC reported 75,450 shares, equal to 0.02% of portfolio, with an estimated market value of $687.

What does the chart on this EPRX ownership page compare?

The chart compares INGALLS & SNYDER LLC's quarterly EPRX portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did INGALLS & SNYDER LLC time their EPRX position?

Based on 13F filing dates vs. subsequent EPRX price moves, INGALLS & SNYDER LLC correctly timed 3 out of 5 reported position changes (60%). The annualised alpha on EPRX relative to SPY over the holding period was +14.6%.

← Back to INGALLS & SNYDER LLC Holdings